Treatment Decisions in Non-Small Cell Lung Cancer

This publication highlights insights from expert stakeholders on the evolving therapeutic landscape of immunotherapy-based treatment regimens through a review of clinical scenarios of patients with non-small cell lung cancer.

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.